Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist

Adv Exp Med Biol. 1996:416:381-7. doi: 10.1007/978-1-4899-0179-8_61.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Chromatography, High Pressure Liquid
  • Double-Blind Method
  • Humans
  • Injections, Intravenous
  • Male
  • Platelet Activating Factor / antagonists & inhibitors*
  • Platelet Activating Factor / pharmacology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / pharmacology*
  • Prodrugs / administration & dosage
  • Prodrugs / pharmacokinetics
  • Prodrugs / pharmacology*
  • Pyridinium Compounds / administration & dosage
  • Pyridinium Compounds / pharmacokinetics
  • Pyridinium Compounds / pharmacology*
  • Spectrophotometry, Ultraviolet
  • Thiazoles / administration & dosage
  • Thiazoles / pharmacokinetics
  • Thiazoles / pharmacology*
  • beta-Thromboglobulin / metabolism*

Substances

  • Platelet Activating Factor
  • Platelet Aggregation Inhibitors
  • Prodrugs
  • Pyridinium Compounds
  • Thiazoles
  • beta-Thromboglobulin
  • ABT 299